Astellas Pharma Total Long-Term Assets 2012-2024 | ALPMY

Astellas Pharma total long-term assets from 2012 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
  • Astellas Pharma total long-term assets for the quarter ending December 31, 2024 were $15.967B, a 17.59% increase year-over-year.
  • Astellas Pharma total long-term assets for 2024 were $15.728B, a 48.73% increase from 2023.
  • Astellas Pharma total long-term assets for 2023 were $10.575B, a 8.43% decline from 2022.
  • Astellas Pharma total long-term assets for 2022 were $11.549B, a 8.51% decline from 2021.
Astellas Pharma Annual Total Long-Term Assets
(Millions of US $)
2024 $15,728
2023 $10,575
2022 $11,549
2021 $12,623
2020 $13,307
2019 $9,373
2018 $9,553
2017 $8,431
2016 $7,485
2015 $7,531
2014 $7,184
2013 $6,578
2012 $7,556
2011 $
2010 $
2009 $
Astellas Pharma Quarterly Total Long-Term Assets
(Millions of US $)
2024-06-30 $15,967
2023-06-30 $10,808
2022-06-30 $11,493
2021-06-30 $12,565
2020-06-30 $13,579
2019-06-30 $10,073
2018-06-30 $9,401
2017-06-30 $9,228
2016-09-30 $8,217
2016-06-30 $7,949
2016-03-31 $7,485
2015-12-31 $7,181
2015-09-30 $6,700
2015-06-30 $6,763
2015-03-31 $7,531
2014-12-31 $7,128
2014-09-30 $7,190
2014-06-30 $7,107
2014-03-31 $9,694
2013-12-31 $3,964
2013-09-30 $3,977
2013-06-30 $4,109
2013-03-31 $10,138
2012-12-31 $5,025
2012-09-30 $4,935
2012-06-30 $4,993
2012-03-31 $5,127
2011-12-31 $5,098
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $17.608B $11.108B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $83.625B 33.00
Zoetis (ZTS) United States $74.024B 27.92
Takeda Pharmaceutical (TAK) Japan $44.801B 9.92
Daiichi Sankyo, - (DSNKY) Japan $43.243B 26.35
Sandoz Group AG (SDZNY) Switzerland $20.284B 0.00
Merck (MKKGY) Germany $18.475B 16.55
United Therapeutics (UTHR) United States $15.992B 15.73
Summit Therapeutics (SMMT) United States $13.894B 0.00
Shionogi (SGIOY) Japan $12.709B 12.73
Neurocrine Biosciences (NBIX) United States $11.876B 36.20
Orion OYJ (ORINY) Finland $7.630B 21.45
Madrigal Pharmaceuticals (MDGL) United States $7.026B 0.00
Corcept Therapeutics (CORT) United States $6.476B 49.06
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.416B 0.00
Stevanato Group S.p.A (STVN) Italy $6.396B 41.41
Grifols, S.A (GRFS) Spain $5.109B 0.00
Ionis Pharmaceuticals (IONS) United States $5.069B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.650B 9.52
Recursion Pharmaceuticals (RXRX) United States $3.517B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.211B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.572B 15.37
Catalyst Pharmaceuticals (CPRX) United States $2.535B 11.49
Hypermarcas (HYPMY) Brazil $2.065B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.065B 0.00
Soleno Therapeutics (SLNO) United States $1.941B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.717B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.620B 0.00
Evotec AG (EVO) Germany $1.581B 0.00
Dyne Therapeutics (DYN) United States $1.383B 0.00
Guardian Pharmacy Services (GRDN) United States $1.264B 0.00
Ardelyx (ARDX) United States $1.223B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.153B 0.00
Indivior (INDV) United States $1.138B 4.94
Ocular Therapeutix (OCUL) United States $1.058B 0.00
Xencor (XNCR) United States $1.054B 0.00
ARS Pharmaceuticals (SPRY) United States $1.053B 0.00
Enliven Therapeutics (ELVN) United States $1.043B 0.00
Harrow (HROW) United States $0.982B 0.00
Collegium Pharmaceutical (COLL) United States $0.941B 5.14
Bioventus (BVS) United States $0.814B 25.72
Avadel Pharmaceuticals (AVDL) Ireland $0.795B 0.00
Cronos Group (CRON) Canada $0.734B 0.00
Relay Therapeutics (RLAY) United States $0.649B 0.00
USANA Health Sciences (USNA) United States $0.623B 11.55
Verve Therapeutics (VERV) United States $0.595B 0.00
Xeris Biopharma Holdings (XERS) United States $0.561B 0.00
Elite Pharmaceuticals (ELTP) United States $0.526B 0.00
OmniAb (OABI) United States $0.514B 0.00
KalVista Pharmaceuticals (KALV) United States $0.511B 0.00
Savara (SVRA) United States $0.455B 0.00
CytoDyn (CYDY) United States $0.440B 0.00
ProKidney (PROK) United States $0.437B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.436B 0.00
Altimmune (ALT) United States $0.435B 0.00
Siga Technologies (SIGA) United States $0.406B 4.74
Organogenesis (ORGO) United States $0.400B 0.00
Zevra Therapeutics (ZVRA) United States $0.398B 0.00
Aldeyra Therapeutics (ALDX) United States $0.387B 0.00
Akebia Therapeutics (AKBA) United States $0.386B 0.00
Oruka Therapeutics (ORKA) United States $0.380B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.377B 152.79
Esperion Therapeutics (ESPR) United States $0.359B 0.00
Tourmaline Bio (TRML) United States $0.314B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.288B 0.00
Aquestive Therapeutics (AQST) United States $0.270B 0.00
Heron Therapeutics (HRTX) United States $0.269B 0.00
Nature's Sunshine Products (NATR) United States $0.255B 15.19
Avita Medical (RCEL) United States $0.247B 0.00
Innate Pharma SA (IPHYF) France $0.243B 0.00
Korro Bio (KRRO) United States $0.239B 0.00
Profound Medical (PROF) Canada $0.224B 0.00
4D Molecular Therapeutics (FDMT) United States $0.209B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.206B 0.00
Lyell Immunopharma (LYEL) United States $0.194B 0.00
MediWound (MDWD) Israel $0.194B 0.00
Larimar Therapeutics (LRMR) United States $0.193B 0.00
Nanobiotix S.A (NBTX) France $0.182B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.178B 0.00
Inhibikase Therapeutics (IKT) United States $0.172B 0.00
Acrivon Therapeutics (ACRV) United States $0.168B 0.00
Nektar Therapeutics (NKTR) United States $0.156B 0.00
Aclaris Therapeutics (ACRS) United States $0.148B 0.00
Silence Therapeutics (SLN) United Kingdom $0.146B 0.00
Inotiv (NOTV) United States $0.137B 0.00
Champions Oncology (CSBR) United States $0.129B 0.00
Telomir Pharmaceuticals (TELO) United States $0.126B 0.00
Lexeo Therapeutics (LXEO) United States $0.123B 0.00
Cassava Sciences (SAVA) United States $0.120B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.120B 0.00
ElectroCore (ECOR) United States $0.115B 0.00
VAXART, INC (VXRT) United States $0.115B 0.00
Journey Medical (DERM) United States $0.112B 0.00
Achieve Life Sciences (ACHV) Canada $0.108B 0.00
Cardiol Therapeutics (CRDL) Canada $0.097B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.092B 0.00
Galectin Therapeutics (GALT) United States $0.092B 0.00
Arch Biopartners (ACHFF) Canada $0.087B 0.00
Metagenomi (MGX) United States $0.087B 0.00
Regulus Therapeutics (RGLS) United States $0.085B 0.00
Nutriband (NTRB) United States $0.084B 0.00
Avalo Therapeutics (AVTX) United States $0.084B 0.00
ESSA Pharma (EPIX) Canada $0.076B 0.00
Assertio Holdings (ASRT) United States $0.076B 19.92
Karyopharm Therapeutics (KPTI) United States $0.075B 0.00
PMV Pharmaceuticals (PMVP) United States $0.074B 0.00
Protara Therapeutics (TARA) United States $0.074B 0.00
Pyxis Oncology (PYXS) United States $0.073B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.071B 0.00
Fractyl Health (GUTS) United States $0.068B 0.00
Vivani Medical (VANI) United States $0.068B 0.00
Mural Oncology (MURA) Ireland $0.066B 0.00
Context Therapeutics (CNTX) United States $0.062B 0.00
Century Therapeutics (IPSC) United States $0.061B 0.00
AleAnna (ANNA) United States $0.060B 0.00
Unicycive Therapeutics (UNCY) United States $0.059B 0.00
FibroGen (FGEN) United States $0.058B 0.00
OptiNose (OPTN) United States $0.057B 0.00
Gain Therapeutics (GANX) United States $0.055B 0.00
AlloVir (ALVR) United States $0.051B 0.00
Iterum Therapeutics (ITRM) Ireland $0.050B 0.00
Rafael Holdings (RFL) United States $0.049B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.049B 0.00
Dominari Holdings (DOMH) United States $0.048B 0.00
Prelude Therapeutics (PRLD) United States $0.046B 0.00
VYNE Therapeutics (VYNE) United States $0.041B 0.00
NRx Pharmaceuticals (NRXP) United States $0.040B 0.00
SCYNEXIS (SCYX) United States $0.039B 0.00
Tempest Therapeutics (TPST) United States $0.038B 0.00
CASI Pharmaceuticals (CASI) China $0.037B 0.00
Surrozen (SRZN) United States $0.037B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.031B 0.00
PolyPid (PYPD) Israel $0.031B 0.00
Incannex Healthcare (IXHL) Australia $0.027B 0.00
BioVie (BIVI) United States $0.027B 0.00
Jupiter Neurosciences (JUNS) United States $0.026B 0.00
Natural Alternatives (NAII) United States $0.025B 0.00
DURECT (DRRX) United States $0.025B 0.00
Scienture Holdings (SCNX) United States $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.021B 0.00
Mannatech (MTEX) United States $0.021B 0.00
Vivos Therapeutics (VVOS) United States $0.020B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
GlycoMimetics (GLYC) United States $0.018B 0.00
MEI Pharma (MEIP) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.017B 0.00
Lipocine (LPCN) United States $0.017B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.015B 0.00
Traws Pharma (TRAW) United States $0.015B 0.00
Biomerica (BMRA) United States $0.014B 0.00
Lyra Therapeutics (LYRA) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
ProPhase Labs (PRPH) United States $0.013B 0.00
Minerva Neurosciences (NERV) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
Nuvilex (PMCB) United States $0.012B 0.00
TherapeuticsMD (TXMD) United States $0.012B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Phio Pharmaceuticals (PHIO) United States $0.011B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Klotho Neurosciences (KLTO) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Talphera (TLPH) United States $0.009B 0.00
Jaguar Animal Health (JAGX) United States $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Relmada Therapeutics (RLMD) United States $0.009B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.005B 0.00
CERo Therapeutics Holdings (CERO) United States $0.005B 0.00
TransCode Therapeutics (RNAZ) United States $0.005B 0.00
Conduit Pharmaceuticals (CDT) United States $0.004B 0.00
SciSparc (SPRC) Israel $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.004B 0.00
China SXT Pharmaceuticals (SXTC) China $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.07
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
SHINECO (SISI) China $0.002B 0.00
Heatwurx (PCSA) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.002B 0.00
Petros Pharmaceuticals (PTPI) United States $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
TNF Pharmaceuticals (TNFA) United States $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00